syn2bio.plCrawled Nov 6, 2026
Coronary artery disease is a major challenge in modern medicine. According to the World Health Organization, cardiovascular diseases cause over 17 million deaths annually, with nearly half resulting from myocardial ischemia. In Poland, around 100,000 hospitalizations occur yearly due to heart attacks, and millions live with chronic coronary disease.
Research into the SYN2 cardiac tracer began in 2013 with analyses of various molecules for their physical, pharmacokinetic properties, and potential in myocardial perfusion imaging. Studies selected a fluorine-18–labeled compound, an isotope with a favorable half-life enabling high-quality imaging and distribution to diagnostic centers.
Compared to other radiopharmaceuticals used in cardiology, SYN2 stands out in:
The Polish Financial Supervision Authority approved the prospectus for Syn2bio, the entity Synektik plans to spin off for cardiac tracer research and commercialization of this radiopharmaceutical with global sales potential. The prospectus supports the issuance of Syn2bio’s shares, which will be allocated to Synektik shareholders. Syn2bio’s debut on the Warsaw Stock Exchange is planned for around mid-2026.
Syn2bio, the new company receiving Synektik’s cardiomarker research, submitted a prospectus to the Financial Supervision Authority for its planned IPO.
Synektik, a provider of advanced medical solutions including medical devices and IT systems, and a leading Polish producer of radiopharmaceuticals, approved a plan to split into two independent entities. The new entity, Syn2bio, will focus on research into new pharmaceutical compounds, including a cardiac tracer—a radiopharmaceutical with global sales potential.
The company maintains transparent relations with capital market participants by sharing information about Syn2bio SA.
Synektik provides full information about Syn2bio SA to investors and the public.
Synektik SA plans to divide by transferring assets to a new company, Syn2bio SA.
Syn2bio SA was established following Synektik SA’s decision to split the company. The new entity, Syn2bio, includes an organized division of Synektik SA’s business covering:
